Literature DB >> 2504366

Hypercalcaemia in malignancy.

S H Ralston, S J Gallacher, U Parel, I T Boyle.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504366      PMCID: PMC1837077          DOI: 10.1136/bmj.299.6692.181-c

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  9 in total

1.  Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.

Authors:  S H Ralston; A A Alzaid; M D Gardner; I T Boyle
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-14

2.  Renal handling of calcium and sodium in metastatic and non-metastatic malignancy.

Authors:  S R Heller; D J Hosking
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

Review 3.  Hypercalcaemia in malignancy.

Authors:  D A Heath
Journal:  BMJ       Date:  1989-06-03

4.  Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.

Authors:  S H Ralston; A A Alzaid; S J Gallacher; M D Gardner; R A Cowan; I T Boyle
Journal:  Q J Med       Date:  1988-10

5.  Etidronate disodium in the management of malignancy-related hypercalcemia.

Authors:  C Hasling; P Charles; L Mosekilde
Journal:  Am J Med       Date:  1987-02-23       Impact factor: 4.965

6.  Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy.

Authors:  S H Ralston; I Fogelman; M D Gardiner; I T Boyle
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-12

7.  Hypercalcaemia of malignancy: evidence for a nonparathyroid humoral agent with an effect on renal tubular handling of calcium.

Authors:  S H Ralston; I Fogelman; M D Gardner; F J Dryburgh; R A Cowan; I T Boyle
Journal:  Clin Sci (Lond)       Date:  1984-02       Impact factor: 6.124

8.  Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia.

Authors:  H P Sleeboom; O L Bijvoet; A T van Oosterom; J H Gleed; J L O'Riordan
Journal:  Lancet       Date:  1983-07-30       Impact factor: 79.321

9.  Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate.

Authors:  J P Bonjour; J Philippe; G Guelpa; A Bisetti; R Rizzoli; A Jung; S Rosini; J A Kanis
Journal:  Bone       Date:  1988       Impact factor: 4.398

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.